Abbott Laboratories — Jan 22, 2026 release

of $1.50 reflects growth of 12 percent – Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percent – Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5% – Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpoint ABBOTT PARK, Ill., Jan. 22, 2026 — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2025. • Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-related sales 1 . • Fourth-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.50, which excludes specified items and reflects growth of 12 percent. • Full-year 2025 sales of $44.3 billion increased 5.7 percent on a reported basis, 5.5 percent on an organic basis, or 6.7 percent when excluding COVID-19 testing-related sales 2 . • Full-year 2025 GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, which excludes specified items and reflects growth of 10 percent. • Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. • Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint. • In November, Abbott announced an agreement to acquire Exact Sciences, a move that will position the compan